Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1797)	10/5/2000 9:11:38 AM
From: Biomaven	Respond to of 52153

Interesting article at TSC about challenges to AFFX: thestreet.com Personally I wish everyone would just cross-license and get on with the science. Note the comment by Lander that there are only 40k genes. (at least 75k of which have already been patented <g>) At a conservative million bucks a gene, that drops the value of the genome to a mere 40 billion. No wait, if there are fewer, each one must be more valuable, right? And if each gene produces multiple proteins, we should be able to get more than a million for a gene (and more than one patent) ... And how about if we start patenting the interactions between genes? There are n**2 of those, even if we only worry about pairwise interactions. And what about protein/protein interactions? Yes, indeed, son/daughter, you should become a patent lawyer. <g> Peter